The Centre for Addiction and Mental Health (CAMH) and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. This novel treatment is a peptide that ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.